Alembic Pharmaceuticals informs about press release

02 Dec 2020 Evaluate

Alembic Pharmaceuticals has informed that its Associate Company, Rhizen Pharmaceuticals SA (Rhizen) has issued a Press Release announcing that it has received approval of its lnvestigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company has enclosed Rhizen's press release tilted ‘Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020’.  Alembic Pharmaceuticals through its wholly owned subsidiary holds 50% ownership in Rhizen.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

770.85 7.95 (1.04%)
23-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1732.20
Dr. Reddys Lab 1307.00
Cipla 1326.10
Zydus Lifesciences 907.90
Lupin 2245.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×